Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Antibody-drug conjugates (ADCs) combine antibodies and cytotoxic payloads for targeted cancer treatment.
• ADCs face challenges including drug resistance, low therapeutic index, and payload toxicity.
• Peptide-drug conjugates (PDCs) emerge as an evolution, replacing antibodies with peptides for enhanced targeting.

Purpose of the Study:

• To review the current landscape of ADCs and PDCs.
• To highlight structural innovations in ADC components.
• To analyze the challenges and future potential of PDCs as next-generation targeted therapies.

Main Methods:

• Literature review and analysis of existing research on ADCs and PDCs.
• Comparative assessment of ADC and PDC structural components and mechanisms.
• Identification and discussion of current challenges in PDC development.

Main Results:

• ADCs offer targeted delivery but have limitations.
• PDCs represent a significant advancement, leveraging peptides for improved targeting.
• Structural innovations in ADCs are paving the way for next-generation conjugates.

Conclusions:

• PDCs show great promise as successors to ADCs in targeted cancer therapy.
• Addressing PDC-specific challenges is crucial for their clinical translation.
• This perspective provides insights for designing and developing novel targeted conjugated drugs.